- HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ:DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm after 12 months.
- It reiterates a Buy rating and a $10 price target.
- Moreover, the analysts highlight that the lower bound of the 95% confidence interval was 22.4%, comfortably exceeding the prespecified 15% threshold.
- The analysts emphasize that the Phase 3 EPITOPE trial was much more conservative in its safety assessment compared to the context of oral immunotherapy Palforzia.
- They note that 1.6% of patients in the Viaskin arm, compared to 0% placebo, experienced an anaphylactic reaction related to or possibly related to treatment while not necessarily requiring epinephrine.
- HC Wainwright specifically compares it to Aimmune Therapeutics Inc's Palforzia.
- Along with black box anaphylactic reaction risk, the analysts note Palforzia demonstrated 9.4% of patients with anaphylaxis in combined studies during dose escalation and up-dosing compared to 3.8% for placebo, highlighting Viaskin's EPIT differentiation from a safety standpoint, while delivering on efficacy with a minimal peanut allergen.
- Price Action: DBVT shares are up 14.54% at $1.75 during the market session on the last check Wednesday.
